Detalhe da pesquisa
1.
Integrative clinical genomics of advanced prostate cancer.
Cell
; 161(5): 1215-1228, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26000489
2.
Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell
; 162(2): 454, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843286
3.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
4.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564933
5.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Cancer
; 129(14): 2169-2178, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060201
6.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
7.
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Lancet Oncol
; 23(11): 1398-1408, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265504
8.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
Int J Cancer
; 150(7): 1166-1173, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605002
9.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
10.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
11.
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
Br J Cancer
; 127(8): 1394-1402, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35715640
12.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 22(11): 1541-1559, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34600602
13.
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
Br J Cancer
; 125(9): 1226-1232, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333554
14.
ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.
Bioinformatics
; 36(9): 2665-2674, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31922552
15.
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
Br J Cancer
; 123(6): 982-987, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32669676
16.
The Lancet Commission on prostate cancer: planning for the surge in cases.
Lancet
; 403(10437): 1683-1722, 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583453
17.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
18.
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 20(4): 556-569, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770294
19.
Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer.
Lancet
; 402(10398): 266-267, 2023 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285866
20.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464